ReleaseMy take on yesterdays pre ASCO release is that it was good but not out of the park, which most, I believe, were expecting after Coffey's hype during his year end phone call. I was surprised with the high number of patients removed from the trial because of toxity. This almost seems similar to what happened during the H&N. Can't imagine they would make the same mistake twice infleuncing the outcome of the trial. Then again after 20 + years nothing coming from ONCY should be a surprise.
Since the main success was with Pfizers paxlitaxel and Pfizerer hasn't shown any interest. So now where do they go to get a partner or buyout. Perhaps the market is askig the same question.